Cagrilintide Phase 1 trial (NCT04209049)
An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal Function
Registry record checked
At a glance
- Phase
- Phase 1
- Status
- Completed
- Enrolment
- 33
- actual
- Start
- 15 Jan 2020 (actual)
- Primary completion
- 5 Jan 2021 (actual)
- Sponsor
- Novo Nordisk A/S
Design
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Normal renal function | Experimental | Drug: NNC0174-0833 | All subjects will receive one dose of NNC0174-0833. |
| Mild renal impairment | Experimental | Drug: NNC0174-0833 | All subjects will receive one dose of NNC0174-0833. |
| Moderate renal impairment | Experimental | Drug: NNC0174-0833 | All subjects will receive one dose of NNC0174-0833. |
| Severe renal impairment | Experimental | Drug: NNC0174-0833 | All subjects will receive one dose of NNC0174-0833. |
Endpoints
Primary endpoint
| Measure | Time frame |
|---|---|
| Area under the plasma NNC0174-0833 concentration-time curve after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36) |
Endpoints
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Maximum observed plasma NNC0174-0833 concentration after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (visit 7, Day 36) |
| Time to maximum observed plasma NNC0174-0833 concentration after a single dose | From baseline (Visit 2, Day 1, pre-dose) until completion of the end of trial visit (Visit 7, Day 36) |
| Number of treatment emergent adverse events (TEAEs) | From time of trial product administration (Visit 2, Day 1) until completion of the end of trial visit (Visit 7, Day 36) |
Eligibility
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Results
Results
No results posted on ClinicalTrials.gov as of 11 Oct 2026.
Renal impairment and a single cagrilintide dose
Both impairment studies sorted adults into four function groups and gave a single cagrilintide injection of 0.6 mg or 0.9 mg.[2]
The kidney arm enrolled 33 people: 14 with normal function, 7 mild, 7 moderate and 5 severe impairment.[2]
Compared with normal kidney function, mean AUC ratios were 1.23, 1.18 and 1.21 for mild, moderate and severe impairment.[2]
Sources
- 1An Open-label Trial Investigating the Pharmacokinetics and the Tolerability of NNC0174-0833 in Subjects With Normal Renal Function and Impaired Renal FunctionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
- 2Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
Found an error? Report a correction.